156 related articles for article (PubMed ID: 8438050)
1. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.
Peters BS; Winer J; Landon DN; Stotter A; Pinching AJ
Q J Med; 1993 Jan; 86(1):5-15. PubMed ID: 8438050
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage.
Dalakas MC; Leon-Monzon ME; Bernardini I; Gahl WA; Jay CA
Ann Neurol; 1994 Apr; 35(4):482-7. PubMed ID: 8154877
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial myopathy caused by long-term zidovudine therapy.
Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy.
Chariot P; Monnet I; Gherardi R
Ann Neurol; 1993 Oct; 34(4):561-5. PubMed ID: 8215243
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R
Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364
[TBL] [Abstract][Full Text] [Related]
7. [Myopathy and zidovudine].
Mateo O; Gato A; Ballesteros P; Benito L; Pontes MJ; Esquinas G
Enferm Infecc Microbiol Clin; 1992 Oct; 10(8):474-6. PubMed ID: 1489776
[TBL] [Abstract][Full Text] [Related]
8. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro.
Semino-Mora MC; Leon-Monzon ME; Dalakas MC
Lab Invest; 1994 Jul; 71(1):102-12. PubMed ID: 7518879
[TBL] [Abstract][Full Text] [Related]
9. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice.
Lebrecht D; Deveaud C; Beauvoit B; Bonnet J; Kirschner J; Walker UA
Arthritis Rheum; 2008 Jan; 58(1):318-26. PubMed ID: 18163507
[TBL] [Abstract][Full Text] [Related]
10. Type B lactic acidosis in an AIDS patient treated with zidovudine.
Aggarwal A; al-Talib K; Alabrash M
Md Med J; 1996 Nov; 45(11):929-31. PubMed ID: 8942169
[TBL] [Abstract][Full Text] [Related]
11. Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine.
Herzberg NH; Zorn I; Zwart R; Portegies P; Bolhuis PA
Muscle Nerve; 1992 Jun; 15(6):706-10. PubMed ID: 1324428
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells.
d'Amati G; Lewis W
Lab Invest; 1994 Dec; 71(6):879-84. PubMed ID: 7528833
[TBL] [Abstract][Full Text] [Related]
13. Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy.
Rosenfeldt FL; Mijch A; McCrystal G; Sweeney C; Pepe S; Nicholls M; Dennett X
Int J STD AIDS; 2005 Dec; 16(12):827-9. PubMed ID: 16336769
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of myopathic findings in 50 patients with the 3243A>G mutation in mitochondrial DNA.
Kärppä M; Herva R; Moslemi AR; Oldfors A; Kakko S; Majamaa K
Brain; 2005 Aug; 128(Pt 8):1861-9. PubMed ID: 15857931
[TBL] [Abstract][Full Text] [Related]
15. Analysis of myopathy in a placebo-controlled zidovudine trial.
Simpson DM; Slasor P; Dafni U; Berger J; Fischl MA; Hall C
Muscle Nerve; 1997 Mar; 20(3):382-5. PubMed ID: 9052824
[No Abstract] [Full Text] [Related]
16. Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy.
Campos Y; Arenas J
Ann Neurol; 1994 Oct; 36(4):680-1. PubMed ID: 7944307
[No Abstract] [Full Text] [Related]
17. Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment.
Panegyres PK; Papadimitriou JM; Hollingsworth PN; Armstrong JA; Kakulas BA
J Neurol Neurosurg Psychiatry; 1990 Aug; 53(8):649-55. PubMed ID: 2170584
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine-associated myopathy.
Paradis J; Calis KA
Am J Hosp Pharm; 1994 Dec; 51(24):3026-8. PubMed ID: 7856620
[No Abstract] [Full Text] [Related]
19. Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers.
Gherardi RK; Florea-Strat A; Fromont G; Poron F; Sabourin JC; Authier J
Ann Neurol; 1994 Nov; 36(5):752-8. PubMed ID: 7979221
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.
Chariot P; Drogou I; de Lacroix-Szmania I; Eliezer-Vanerot MC; Chazaud B; Lombès A; Schaeffer A; Zafrani ES
J Hepatol; 1999 Jan; 30(1):156-60. PubMed ID: 9927163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
